Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 4/20 | 0.33 |
| ▸ | CPT2 | P23786 | 2/20 | 0.33 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581627 | 0.90 | IRAK4 (0.33) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL3583149 | 0.88 | IRAK4 (0.32) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL13031191 | 0.87 | GRIN2B (0.33) | GPR119GRIN2BLMNAPTGS2PTGS1 | |
| SCHEMBL3584110 | 0.83 | IRAK4 (0.34) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL3590320 | 0.83 | IRAK4 (0.33) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL3589601 | 0.83 | CPT1A (0.33) | IRAK4CPT1ACPT2CPT1BGPR119 | |
| SCHEMBL3591790 | 0.83 | PSEN1 (0.36) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL3581779 | 0.83 | TLR9 (0.34) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL3585326 | 0.82 | KDM4E (0.32) | IRAK4CPT1ACPT2CPT1BGRIN2B | |
| SCHEMBL3588152 | 0.82 | CXCR3 (0.38) | IRAK4CPT1ACPT2CPT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291578-A1 | FUNGICIDAL AZOCYCLIC AMIDES | CORTEVA AGRISCIENCE LLC | 2015-10-15 | — | — | US | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | claimed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291578-A1 | FUNGICIDAL AZOCYCLIC AMIDES | ARG1, NAT1, CHRM1 | IRAK4 3194/4885CPT1A 1529/4885CPT2 3009/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | IRAK4 367/4885CPT1A 1947/4885CPT2 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.